European Lithium: A Greenland Bet Hangs on a Nasdaq Partner’s Slide
The arithmetic behind European Lithium’s proposed takeover has become brutally simple: every percentage point shed by Critical Metals…
European Lithium’s Merger Countdown: Cash Condition, Greenland Test, and a 19% Monthly Slide
European Lithium is navigating a complex web of deadlines as it pushes toward a transformative merger with Critical…
Novo Nordisk’s New Orleans Moment: Can CagriSema Data Reverse a 44% Slide?
Novo Nordisk’s 44% stock slide faces pivotal ADA test: Phase 3 CagriSema data for diabetes/obesity could restore confidence…
Novo Nordisk’s Pipeline Showdown: Can CagriSema and Zenagamtide Reverse the Stock’s Slide?
Novo Nordisk unveils CagriSema Phase 3 data at ADA after stock drop; oral Wegovy pill shows strong early…
Novo Nordisk’s Buyback Blitz and FDA Fast-Track Mask a Steep Profit Slide
Novo Nordisk spends billions on share repurchases but faces a 50% stock drop, 2026 revenue decline, and fierce…
Novo Nordisk Bets on AI and Subscriptions to Counter a Steep Slide
Novo Nordisk shares surge as the firm partners with OpenAI to accelerate drug development and expands Wegovy subscription…
Novo Nordisk Bets on AI and New Products to Reverse Steep Share Slide
Novo Nordisk shares rebound on UK Wegovy pen approval. The firm combats a weak outlook with an OpenAI…